Introduction
Since the original report of its use in the treatment of peptic ulcer (Doll et al., 1962 ) the value of carbenoxolone sodium tablets (Biogastrone) in the treatment of gastric ulcer has been well established (Doll et al., 1965; Horwich and Galloway, 1965; Turpie and Thompson, 1965) . The original study (Doll et al., 1962) showed the tablet form cf carbenoxolone to be ineffective in duodenal ulcer therapy, and more recently a positioned-release capsule (Duogastrone), which is said to prevent the release of the drug in the stomach, has been developed (Galloway, 1968) .
However, reports of its value in the treatment of duodenal ulcer based on radiological and symptomatic assessment have been conflicting. A number of trials have shown significant improvement with carbenoxolone (Craig et al., 1967; Lawrence et al., 1968; Amure, 1970) , while in others reports have been equivocal or unfavourable (Colin-Jones et al., 1968; Montgomery et al., 1968; Cliff and Milton-Thompson, 1970) .
These conflicting results may be partly due to the difficulties of radiological diagnosis in duodenal ulceration and subsequent radiological assessment of ulcer healing. Similarly, symptoms may provide an inaccurate guide to the presence of an ulcer or its subsequent course during treatment. Duodenoscopy is a safe and acceptable procedure for direct examination of the duodenal bulb , and we report a double-blind study of carbenoxolone sodium capsules in the treatment of duodenal ulcer, with patient selection and follow-up based on endoscopic examination of the duodenal bulb.
Method
Patients with clinical and radiological evidence of a duodenal ulcer were submitted to duodenoscopy. The exampation technique has previously been described (Salert-eS-t al., 1972) . The initial examination was always carried out with a forward viewing instrument so that the oesophagus and stomach could also be fully examined. After duodenal intubation 40 mg of hyoscine N-butylbromide was given intravenously to paralyse the duodenal bulb, which allows a more complete examination and facilitates photography. In some cases a complete view of all the bulb with the forward viewing instrument was not possible, and in these cases a lateral viewing instrument was also employed. In each patient the instrument which gave the better view was used at all subsequent examinations. At subsequent examinations endoscopic healing was recorded if there was a definite reduction in ulcer size or if duodenal inflammation or oedema was noticeably improved.
As the magnification produced by a fibreoptic system varies inversely with the distance between the object and the distal objective of the endoscope it was necessary to assess ulcer size at each examination. In most cases this could be done by comparison with an endoscopic landmark such as the superior duodenal fold. If the ulcer was in a position where no such landmark was in view, then size was compared with the opened blades of the endoscopic biopsy forceps. The forceps were passed down the instrument, opened, and advanced on to the mucosa alongside the ulcer. At subsequent examinations any variation in ulcer size due to differences in magnification would be reflected in apparent changes in relevant size.
Patients 
Results
Of 31 patients admitted to the trial 17 were in the active group and 14 in the placebo group (Table I) . Twenty-six patients presented with dyspepsia alone and five with a haematemesis. Only five of the patients were women. In 11 cases (35%) barium-meal examination failed to show an ulcer crater and in two of these the duodenum was radiologically normal. the carbenoxolone group (12/15) compared with the placebo group (7/13) ( Table II) . There was no difference in numbers noting symptomatic improvement in the two groups in the later stages of treatment, but at the-final assessment 7 out of 14 patients in the active group compared with 3 out of 13 patients in the placebo group were free of pain (P >0 05).
Endoscopic Assessment.-There was a statistically significant difference (P <0-01) in the number of patients with endoscopic evidence of ulcer healing at 2-4 weeks in the carbenoxolone group (13/16) compared with the placebo group (4/13) ( Table  III) . The difference was still significant (P <0 05) at 6-8 weeks, but there was no difference between the two groups at Side Effects.-There were statistically significant changes in the mean plasma potassium (P <0-001) and mean systolic blood pressure (P <0-025) after only two weeks of treatment with carbenoxolone. There were less important changes in the mean diastolic pressure and weight, although the weight of three patients increased between 10 and 14 lb (4 5 and 6-5 kg) while on active drug. Five patients required potassium supplements and two required a thiazide diuretic. One patient developed symptoms of hypokalaemia despite potassium supplements, and treatment was stopped at 10 weeks. This patient had no symptoms and an apparently normal duodenal bulb at her final assessment. Another patient had treatment stopped inadvertantly at six weeks because of ankle oedema, but as her symptoms had improved and the ulcer had virtually healed treatment was not reinstituted and she had a normal duodenal bulb at 12 weeks. These were the only two women on carbenoxolone for longer than four weeks. .
RELATION BETWEEN ENDOSCOPIC AND SYMPTOMATIC ASSESSMENTS
The mechanism of duodenal ulcer pain and the anatomical site from which it is referred are still unknown. Most theories incrimiinate gastric acid, abnormal intestinal motility, duodenal inflammation, or a combination of these as the basic causative factor, and the oesophagus, stomach, and duodenum have all been claimed to be the site from which pain is referred. The problem has been reviewed in detail (Ivy et al., 1950; Bockus, 1963) . Hurst (1911) postulated that dyspeptic symptoms were due to altered motility and increased tone in the stomach. Radiological and pressure studies have shown that the pain of duodenal ulcer occurred at the same time as increasing motility and contraction of the duodenal bulb (Wilson, 1928; Patterson and Sandweiss, 1942) . Pain has also been related to increased gastric contractions (Ruffin et al., 1953) .
The production of epigastric pain by the application of acid to the gastric or duodenal mucosa of normal subjects and patients with a peptic ulcer has been extensively studied (Talma, 1884; Palmer, 1926; Smith, 1955) . Epigastric pain has also been produced by distention of the lower oesophagus (Polland and Bloomfield, 1931) and by application of acid to the lower oesophagus in patients with oesophagitis (Bernstein and Baker, 1958) or a duodenal ulcer (Earlam, 1970) . In ulcer patients with pain localized to the epigastrium perfusion of the lower oesophagus with dilute acid produced identical pain in most patients. The same procedure failed to produce pain in those with illlocalized dyspepsia.
As the activity of a duodenal ulcer can be accurately assessed by duodenoscopy the natural history of the disease and especially the relation of symptoms to the presence or absence of an ulcer crater can now be studied in more detail. A comparison of endoscopic findings with symptomatic assessment at each stage The side effects of carbenoxolone include oedema, hypertension, and hypokalaemia, probably due to an aldosterone-like effect of the drug (Baron and Nabarro, 1968; Hausmann and Tarnoky, 1968) . Rarely, the hypokalaemia may cause a myopathy and nephropathy (Mitchell, 1971) . The dose of carbenoxolone used in this study was higher than has previously been recommended for duodenal ulcer therapy, and side effects might therefore be expected to be more prominent. The changes in mean plasma potassium and mean systolic blood pressure are shown in Table IV Erickson, 1966; Harrison, 1968; Katz et al., 1969; Kaye et al., 1969; Kleeman et al., 1970; Siddiqui and Kerr, 1971) .
Before dialysis bone disease rarely causes symptoms. Radiographic appearances and plasma biochemistry are poor indices of renal osteodystrophy, particularly in dialysed patients, and diagnosis is imprecise without bone biopsy (Katz et al., 1969; Bishop, et al., 1971) . Histologically there may be a combination of osteomalacia, osteitis fibrosa, and osteosclerosis (Follis and Jackson, 1943). Osteoporosis is rare (Garner and Ball, 1966; Kyle, 1969; Stanbury, 1969) .
After dialysis treatment has been started the bone disorder may be similar to that affecting non-dialysed patients (Pendras, 1969) . However, dialysed patients can develop a different form of disease attributed to dialysis itself (Harrison, 1968; Siddiqui and Kerr, 1971; Woods et al., 1972) . In this disorder pain and unhealed pathological fractures are common; there is periarticular osteoporosis on radiography and histological examination shows a reduced volume of mineralized bone, increased osteoid, and little osteitis fibrosa (Siddiqui and Kerr, 1971) . In Oxford florid bone disease in dialysed patients is rare. Histological abnormalities are more frequent (Woods et al., 1972) but less often defined by measurement of plasma calcium, phosphate, and alkaline phosphatase than in non-dialysed patients.
We have studied the histological changes in sequential bone biopsy specimens from dialysed patients from the beginning of treatment to decide whether the natural history of bone disease due to chronic renal failure hitherto described (Stanbury and Lumb, 1966 ) is altered by prolonged haemodialysis.
